4.7 Article

Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi In Vitro and In Vivo

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 11, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00284-22

Keywords

Chagas disease drug discovery; drug combination; drug repurposing; chloroquine; benznidazole

Funding

  1. Fundacao de Amparo a Pesquisa de Sao Paulo FAPESP [16/15209-0]
  2. Brazilian Council for Research-CNPq [304620/20165, 304891/2019-3]
  3. FAPESP [2014/50708-2]
  4. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-CAPES [88887.353390/2019-00]
  5. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq [141635/2014-2]
  6. CNPq [BPP 306037/2019-0]
  7. Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro/FAPERJ [E-26/202.572/2019]
  8. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [16/15209-0] Funding Source: FAPESP

Ask authors/readers for more resources

The study investigated the effects of repurposed drugs chloroquine and colchicine on the treatment of Chagas disease, and found that the combination of chloroquine and benznidazole could enhance the trypanocidal activity of benznidazole, reducing the required dosage. In vivo experiments in mice also showed the effectiveness of the combination therapy.
Drug combinations and drug repurposing have emerged as promising strategies to develop novel treatments for infectious diseases, including Chagas disease. In this study, we aimed to investigate whether the repurposed drugs chloroquine (CQ) and colchicine (COL), known to inhibit Trypanosoma cruzi infection in host cells, could boost the anti-T. cruzi effect of the trypanocidal drug benznidazole (BZN), increasing its therapeutic efficacy while reducing the dose needed to eradicate the parasite. The combination of BZN and COL exhibited cytotoxicity to infected cells and low antiparasitic activity. Conversely, a combination of BZN and CQ significantly reduced T. cruzi infection in vitro, with no apparent cytotoxicity. This effect seemed to be consistent across different cell lines and against both the partially BZN-resistant Y and the highly BZN-resistant Colombiana strains. In vivo experiments in an acute murine model showed that the BZN+CQ combination was eight times more effective in reducing T. cruzi infection in the acute phase than BZN monotherapy. In summary, our results demonstrate that the concomitant administration of CQ and BZN potentiates the trypanocidal activity of BZN, leading to a reduction in the dose needed to achieve an effective response. In a translational context, it could represent a higher efficacy of treatment while also mitigating the adverse effects of high doses of BZN. Our study also reinforces the relevance of drug combination and repurposing approaches in the field of Chagas disease drug discovery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available